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Abstract  
 
The poor prognosis of Glioblastoma Multiforme (GBM) is mainly attributed to drug resistance 
mechanisms and to the existence of a subpopulation of glioma stem cells (GSCs). Multi-target 
compounds able to both affect different deregulated pathways and the GSC subpopulation could 
escape tumour resistance, and most importantly, eradicate the stem cell reservoir.  
In this respect, the simultaneous inhibition of Phosphoinositide-dependent kinase-1 (PDK1) and 
Aurora Kinase A (AurA), each one playing a pivotal role in cellular 
survival/migration/differentiation, could represent an innovative strategy to overcome GBM 
resistance and recurrence. 
Herein, the cross-talk between these pathways was investigated, using the single-target reference 
compounds MP7 (PDK1 inhibitor) and Alisertib (AurA inhibitor). Furthermore, a new ligand, 
SA16, was identified for its ability to inhibit the PDK1 and the AurA pathways at once, thus 
proving to be a useful tool for the simultaneous inhibition of the two kinases. SA16 blocked GBM 
cell proliferation, reduced tumour invasiveness, and triggered cellular apoptosis. Most importantly, 
the AurA/PDK1 blocker showed an increased efficacy against GSCs, inducing their differentiation 
and apoptosis. To the best of our knowledge, this is the first report on combined targeting of PDK1 
and AurA. This drug represents an attractive multi-target lead scaffold for the development of new 
potential treatments for GBM and GSCs.  
 
Key words: Glioblastoma Multiforme; glioma stem cells; phosphoinositide-dependent kinase-1; 
Aurora Kinase A; multi-target compounds.  
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Introduction 
Glioblastoma (GBM), a grade IV glioma, is a brain tumour displaying a high rate of recurrence and 
poor prognosis due to its invasive nature1. Current GBM therapies, including radiation followed by 
the chemotherapeutic agent temozolomide (TMZ), do not yield definitive effects, and the five year 
survival rate for GBM is less than 5% in adults2. GBM relapse is ascribable to the invasive nature of 
this tumour, as well as to its resistance to therapy.3, 4 The incidence of GBM has been related to 
genetic and molecular alterations of different signalling pathways, including the epidermal growth 
factor receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)/Akt. In particular, the 3-
Phosphoinositide-dependent kinase-1 (PDK1) inhibition has been suggested to block the oncogenic 
cellular processes5, 6. Moreover, PDK1 phosphorylates and activates Akt, thus playing a pivotal role 
in cell survival and tumorigenesis6. Overexpression of PDK1 correlates with an aggressive 
phenotype and poor prognosis7. Therefore, drugs targeting the PDK1/Akt pathway have emerged as 
one of the potential treatments for GBM8-10. However, specific target drugs, including those against 
PDK1, did not show a significant clinical efficacy11, and preclinical studies on PDK1 inhibitors 
have been hampered by the lack of peculiar proof-of-concept molecules5,12-14. In fact, canonical 
drug resistance processes include an increased expression of efflux pumps, drug target alterations, 
over-activation of pro-survival pathways15, and most important, clonal heterogeneity 16, 17.  
Recently, GBM recurrence and resistance to therapies have also been related to the presence of 
GBM stem-like cells (GSCs), a sub-population of multipotent tumour-initiating cells displaying 
stem cell-like characteristics18, 19. Aggressiveness and unresponsiveness of gliomas have been 
correlated with the number of GSCs3, and long-term temozolomide (TMZ) treatment has been 
shown to favour the emergence of drug-resistant GBM cells20, indicating that a stem cell-oriented 
therapy is needed to prevent GBM recurrence and to improve the outcome of treatments.  
Eradication of the GSC reservoir, by blockade of key pathways involved in stem cell maintenance, 
has been found to effectively reduce their tumorigenic potential21, 22. Among these pathways, the 
Aurora kinase A (AurA) has emerged as an effective target. AurA is a serine–threonine kinase that 
plays a pivotal role in cellular proliferation and differentiation of several tumours, including GBM23, 
24. In particular, AurA is expressed in gliomas and is associated with patient survival, thus 
representing a potential therapeutic target for GBM25. More important, blocking the AurA pathway 
resulted in inhibition of GSC colony formation and potentiation of the common GBM 
chemotherapeutics23. On the basis of these considerations, a multi-target approach16 that is able to 
impact multiple deregulated and escape pathways, and deplete the GSC reservoir, may offer the 
most promising strategy for the treatment of GBM and minimize drug resistance. Among these 
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approaches, the simultaneous disruption of PDK1 and AurA, each one playing a pivotal role in the 
cellular survival/migration/differentiation, could represent an innovative strategy to overcome GBM 
resistance and recurrence. In this respect, a few compounds, classified as PDK1 inhibitors, have 
been shown to also affect AurA activity. For instance, OSU-03012, a PDK1 inhibitor, was found to 
affect multiple cellular targets, including the AurA one, in neuroblastoma and other cancer cells26, 
thus supporting the aforementioned mechanistic rationale (Fig. 1).  
Herein, the molecular mechanisms at the basis of a simultaneous PDK1/AurA inhibition were 
explored in different GBM cell lines, as well as in a GBM-derived stem-like culture. As a first step, 
the standard PDK1 inhibitor, MP712, and the AurA blocker Alisertib (MLN8237)23 were used as 
reference compounds to investigate the functional crosstalk between the two pathways in GBM. 
Furthermore, starting from previously synthesized PDK1 inhibitors, namely OXID-pyridonyl 
hybrids9, 10, we identified SA16 as a new ligand able to inhibit both the PDK1 and the AurA 
pathways at once and thus useful in establishing the preclinical proof of mechanism for the 
simultaneous inhibition of these two pathways (Fig. 1). The new identified compound decreased 
GBM cell proliferation, triggered cellular apoptosis and reduced cell invasiveness. Moreover, this 
novel AurA/PDK1 blocker showed a marked efficacy on GSCs by inducing differentiation and 
apoptosis.  
To the best of our knowledge, this is the first study reporting a combinatorial treatment strategy 
based on the simultaneous inhibition of PDK1 and AurA. Furthermore, we identified an innovative 
PDK1/AurA dual-target molecule which could represent an attractive lead scaffold for the design 
and synthesis of new multi-target treatments for GBM and, most importantly, for GSCs. 
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Results and Discussion 
The combined inhibition of PDK1 and AurA affects GBM cell proliferation. 
In order to study the combined effects of PDK1 and AurA inhibition, the U87MG cells were chosen 
as representative GBM cell line, since they are characterised by: i) the lack of the tumour 
suppressor phosphatase and tensin homologue (PTEN), a negative regulator of the Akt pathway27, 28, 
and ii) the expression of a functional AurA25.  
First, we assessed the effects on adherent U87MG cell proliferation following combined inhibition 
of the two kinases. The experiments were performed in the presence of the PDK1 inhibitor MP7, 
alone or in combination with the AurA inhibitor, Alisertib. These reference compounds were used 
starting from a concentration corresponding to the IC50 value on the target kinases
29, 30. 
Following 72 h treatment, MP7 alone did not show a significant inhibition of GBM proliferation 
(Fig. 2A), consistent with previous reports12. Indeed, MP7 has been shown to have only minimal 
effects on monolayer cell growth in several cancer cell lines, with IC50 values in the micromolar 
range12, suggesting that PDK1 activity is not rate-limiting for cell proliferation but rather in cell 
migration/invasion12 . 
Alisertib alone slightly reduced U87MG cell proliferation (Fig. 2A), showing a significant effect of 
inhibition at 1.5 µM. Consistent with our data, an anti-proliferative effect was reported recently by 
Lehman and co-workers in monolayer GBM cell lines, including U87MG cells25, with IC50’s 
ranging from 60 to 225 nM25. An increased blockade of GBM proliferation was noticed when the 
cells were challenged simultaneously with MP7 and Alisertib: the combined treatment with the two 
compounds showed synergic/additive anti-proliferative effects at all the concentrations tested when 
compared to single-treated cells (Fig. 2A), with a maximal percentage of inhibition of 58.5 ± 4.9 %. 
Further experiments will clarify if MP7 and Alisertib produce a synergic or rather an additive effect. 
Cell counting confirmed that MP7 and Alisertib administered individually slightly affected U87MG 
cell viability at the highest concentration (Supplementary Fig. 1). When U87MG cells were probed 
simultaneously with the two inhibitors, a significant amplification in the decrease of live cells was 
observed with respect to single-treated cells (Supplementary Fig. 1); at the highest concentrations, 
MP7 and Alisertib significantly enhanced the number of dead cells as well (Supplementary Fig. 1). 
These data demonstrate that the reduction of GBM proliferation shown by the MTS assays can be 
attributed, at least in part, to a decrease of U87MG live cells. 
Taking into account the heterogeneity of cancer cell lines, and with the aim of further consolidating 
our data, additional proliferation experiments were performed using different GBM cell lines (i.e. 
ANGM-CSS and U343MG cells). Indeed, these cells present slight differences in motility and 
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invasiveness, and different expression of proteins involved in tumour progression, angiogenesis and 
apoptosis 31. The AuraA inhibitor Alisertib lead to a significant reduction of MTS measurements 
starting from 150 nM in U343MG and ANGM-CSS cells (Supplementary Fig. 2A and B). Similarly 
to what observed in U87MG cells, MP7 did not cause a significant decrease of U343MG or 
ANGM-CSS proliferation (Supplementary Fig. 2A and B). In contrast, the combination of MP7 and 
Alisertib showed greater effects with respect to single- treated cells (Supplementary Fig. 2A and B). 
Thus, even with the great heterogeneity of GBM, the combined use of MP7 and Alisertib showed 
promising effects in the three tested cell lines, suggesting that the simultaneous inhibition of PDK1 
and AurA can be a useful strategy to inhibit GBM cell proliferation. 
 
The combined inhibition of PDK1 and AurA affects GSC proliferation and induces their 
differentiation.  
GSCs are the self-renewing compartment of cancers, thus representing an essential target of 
innovative therapies. Both PDK1 and AurA have been demonstrated to play an important role in 
GSC survival/differentiation: recent evidences suggest that blocking PDK1 is essential to induce 
GSC apoptosis4; similarly, the inhibition of AurA has been shown to result in antiproliferative 
effects towards GSCs23. Therefore, in order to shed light on the effects elicited by the combined 
inhibition of the two kinases, Alisertib and MP7 were probed on GSCs isolated from U87MG cells.  
The formation of GSC neurospheres in vitro was obtained using a specific neural stem-cell (NSC) 
medium, as previously described32. Consistent with literature data33, neurospheres were confirmed 
to contain a higher portion of GSCs than the monolayers cells (Supplementary Fig. 3A). GSCs 
obtained from U87MG cells showed significantly more CD133/Nestin+ cells and a smaller 
percentage of GFAP+ cells than whole U87MG cells, as shown by real time PCR analysis 
(Supplementary Fig. 3B).  
To verify the methodological reliability of the assay, the colony-forming ability of the neurospheres 
and their chemoresistance, which are a key feature of GSCs, were evaluated. As demonstrated in 
Supplementary Figure 4, the sphere formation ability was significantly enhanced in GSCs with 
respect to whole U87MG population (47.5% GSC, 9.9% U87MG, p<0.001). These data indicate 
that GSCs are highly clonogenic and possess self-renewal ability, and that the U87MG adherent 
cells retain a slow stem potential. 
Challenging cells with the alkylating agent TMZ for 72 h showed a reduction in cell proliferation of 
50.0 ± 2.7 and 15.0 ± 3.5 in U87MG and in GSCs, respectively (Supplementary Fig. 5, p<0.001). 
These data demonstrate that stem-like GBM cells exhibited a higher resistance to TMZ with respect 
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to U87MG adherent cells, and overall confirm the methodological consistency of neurosphere 
isolation. 
Then, the effects of MP7 and Alisertib administered as single agents and in a combinatorial fashion, 
were assessed in GSCs. Consistent with the data obtained in U87MG cells, MP7 alone showed 
slight effects on tumorsphere proliferation (Fig. 2B). It can be speculated that PDK1 inhibition is 
related to GSC formation rather than to their proliferation. Indeed, PDK1 has been shown to deplete 
the cancer stem cell (CSC) population in highly invasive breast cancer cells by decreasing 
tumorspheres formation but not their proliferation34. In contrast, Alisertib induced anti-proliferative 
effects on GSCs, in a concentration-dependent manner (Fig. 2B), thus demonstrating that AurA 
inhibition shows a great efficacy in neurosphere cells. Indeed, GSCs have been shown to be highly 
disposed to aberrant cell division and polyploidization, with a pronounced change in the dynamic of 
mitotic centrosome maturations, and thus are strongly dependent on AurA35. In a recent work, it has 
been reported that moderate AurA inhibition is linked to spindle defects, polyploidization and a 
dramatic increase in cellular senescence35. Consistent with these findings, Alisertib treatment has 
been shown to inhibit the colony-formation ability of GSCs isolated from patients with IC50 in the 
low nanomolar range23. 
The combination of the two compounds decreased GSC proliferation, in a concentration-dependent 
manner, with percentages of inhibition significantly higher with respect to those obtained in single-
treated GSCs (Fig. 2B).  
Similar results were obtained in MTS experiments using neurospheres isolated from U343MG 
(Supplementary Fig. 6A) or ANGM-CSS (Supplementary Fig. 6B). 
Cell counting of U87MG-derived GSCs confirmed that Alisertib and, to a minor extent, MP7 were 
able to decrease the number of viable cells (Supplementary Fig. 7). When combined together, GSC 
viability was further reduced with respect to single-treated cells (Supplementary Fig. 7). As 
observed in U87MG cells, when used at the highest concentrations (i.e. 1.5 µM Alisertib and 2.5 
µM MP7), a significant enhancement in the number of dead cells was evidenced (Supplementary 
Fig. 7). 
Globally, these preliminary results suggest that the combined use of 1.5 µM Alisertib and 2.5 µM 
MP7 efficaciously affect proliferation/viability of the GSC subpopulation. 
Subsequently, the effects of MP7, Alisertib and their combination on GSC morphology were 
evaluated. To this purpose, 1.5 µM Alisertib/2.5 µM MP7 was chosen as the representative 
combination of the two inhibitors. The cells were incubated with 2.5 µM MP7, alone or in 
combination with 1.5 µM Alisertib for seven days. The two compounds, when administered 
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individually, led to a reduction in the area occupied by the neurospheres (Fig. 3A and B); these 
effects were particularly evident in cells treated with Alisertib. Moreover, after treatment with 
Alisertib, GSCs also showed a modest but significant outgrowth of cellular processes (Fig. 3A and 
C), implying that AurA blockage can induce GSC differentiation. Consistent with this hypothesis, 
the AurA inhibitor AKI603 has been shown to promote cell differentiation of chronic myeloid 
leukaemia cells36. When MP7 and Alisertib were given in combination, a synergic/additive effect on 
the reduction of neurospheres’area was evidenced (Fig. 3A-B), thus suggesting that the combined 
inhibition of PDK1 and AurA could be a useful strategy to inhibit GSC proliferation. Further 
experiments will be needed to clarify the role of each kinase in survival and differentiation of 
tumour stem-like cells and the mechanism responsible for the enhanced response elicited by the 
combined inhibition of both pathways. 
 
Molecular Modeling 
Aiming at identify new scaffolds for the synthesis of novel PDK1 inhibitors, we have designed a 
new class of OXID-pyridonyl compounds9, 10. Among these hybrids we developed SA16 (Fig. 1B), 
which was identified as a putative ligand with the ability to inhibit both the PDK1 and AurA kinases 
at once. SA16 was originally designed as a PDK1 inhibitor by combining two pharmacophoric 
moieties known to bind the ATP binding site and the DFG-out pocket of PDK1, through a 
phenylglycine linker. Since many published data report that several PDK1 inhibitors with a high 
grade of hydrophobicity (i.e. OSU-03012 and BX795) also show affinity for AurA, we decided to 
investigate the activity of SA16 against other kinases. Consequently, SA16 was subjected to FRET-
based Z′-Lyte assay (Invitrogen) against 56 kinases at 500 nM concentration (see Supporting 
information Table 1). We thus found that SA16 possessed a significant inhibition potency against 
both PDK110 (IC50 = 416 nM) and Aur A (IC50 = 35 nM), suggesting that this compound could be 
studied as a prototype of dual PDK1/Aur A inhibitor. 
To gain insights into the mechanism of dual PDK1/AurA inhibition and to elucidate the binding 
mode of SA16, we carried out molecular docking calculations. In a previous computational study 
we showed that OXID-pyridonyl hybrid compounds most likely bind to the DFG-out conformation 
of PDK110. The docking analysis presented here shows that SA16 inserts its 1-[3,4-difluorobenzyl]-
pyrid-2-one moiety into a pocket, characteristic of the DFG-out conformation, carved by Met-134, 
Leu-137, Phe-142, Val-143, Leu-196, Leu-201, His-203, Ile-221, Asp-223 and Ala-227 (Fig. 4A). 
Within such pocket, several CH-π interactions are established by the 3,4-difluorobenzene ring with 
Leu-137, Leu-196 and Asp-223 and by the 2-pyridone ring and Val-123. Additionally, the amidic 
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carbonyl and the carbonyl group in the 2-pyridone ring engage in hydrogen bonds with the side 
chain of Lys-111 and the Asp-223 backbone NH, respectively. As previously observed for analogue 
compounds10, SA16 positions itself in a way that, while still allowing to form CH-π interactions 
with Val-143, Leu-212 and Thr-222, prevents it from establishing hydrogen bonds with the hinge 
region residues (i.e. Ser-160 and Ala-162), likely to minimize steric clashes between the phenyl ring 
on the methylene of the linker and Ser-94 and Val-96. Specifically, a 100ns-long MD simulation 
performed on an analogue compound confirmed this finding, suggesting that it is not an artifact of 
the rigid-docking procedure. However, the formation of a salt bridge between the imidazole ring, 
which is likely protonated owing to a favorable electrostatic environment, and Glu-166 could at 
least partially compensate for the loss of these interactions.  
Unlike the binding to PDK1 described above, the AurA conformation that binds to SA16 is not 
known, and the fact that the pocket characteristic of the DFG-out conformation seems to be 
narrower in AurA than in PDK1 casts some doubts on the likelihood that SA16 binds the same way 
to both enzymes. Indeed, not only the αC helix is more structured and closer to the N-terminal lobe 
in AurA than in PDK1, but some of the DFG-out pocket lining residues in AurA (Gln-185, Leu-194 
Arg-225) are relatively bulkier, as compared to those found at the corresponding positions in PDK1 
(Met-134, Val-143 and His-203). Overall these two factors contribute to make the DFG-out pocket 
of AurA narrower, likely hampering an efficient accommodation of the 1-[3,4-difluorobenzyl]-
pyrid-2-one moiety. A further issue in the selection of a suitable receptor structure for docking 
calculations is the high conformational variability of AurA, which makes this protein a challenging 
system to treat via molecular modeling approaches. Indeed, in addition to the inherent flexibility of 
the glycine-rich loop common to most kinases, it is known that inhibitors can induce structural 
changes in AurA leading not exclusively to the canonical “in”/“out” states, but also to a number of 
other distinct conformations of the DFG motif37-43. It was thus not practical to pick out a-priori the 
most suitable receptor conformation. A more exhaustive approach had therefore to be adopted to 
identify the binding mode of SA16 in AurA. Accordingly, seven AurA structures in complex with 
different ligands, representative of just as many different conformations, were selected for docking 
calculations (see Supporting information for details on the selection criteria, Supplementary Table 
2). 
Docking calculations were able to assign unambiguously a clear binding mode for SA16 only in one 
of the selected structures (PDB code: 4UZH). In this case, results converged to mostly one solution, 
depicted in Figure 4C, regardless of the protonation state considered for the imidazole ring. 
Specifically, the ((Z)-3-((1H-imidazol-4-yl) methylene)indolin-2-one) moiety inserts within the 
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hinge region of AurA establishing CH-π interactions with Leu-139, Val-147, Ala-160, Leu-263, 
together with hydrophobic contacts with Leu-194, Leu-210 and Tyr-212. Moreover, the carbonyl 
group of the indolin-2-one ring and the Nδ-H of the imidazole engage in hydrogen bonds with Ala-
213 NH and CO backbone groups, respectively. Most of the docking poses feature a charged or Nδ-
protonated imidazole: however, we believe that the latter is the more likely protonation state, owing 
to its close proximity to Arg-220 and Arg-137 in the binding mode predicted by docking. Hydrogen 
bonds are also formed between the carbonyl oxygen of the amidic groups linked to both the indolin-
2-one and the 2-pyridone rings and Lys-162. The 3,4-difluorobenzene ring is favorably hosted in a 
quite large hydrophobic pocket, where the 3,4-difluorobenzene ring makes several CH-π, CH-F and 
other hydrophobic interactions with Phe-144, Lys-162, Leu-164, Leu-169, Val-174, Gln-177, Leu-
178, Leu-208, Phe-275.  
In conclusion, we believe that the binding mode predicted by the docking for SA16 to AurA could 
reasonably justify the low nanomolar activity displayed by the ligand. However, we cannot rule out 
that some large structural rearrangements specifically triggered by SA16, may take place, 
potentially leading to an unpredictable different conformation of AurA. An X-ray crystallographic 
structure of the AurA-SA16 complex will ultimately have to be solved before plausibly discarding 
this possibility.  
 
The dual-target compound blocks GBM proliferation, but lacks toxicity in normal cells. 
First, the effects of SA16 on U87MG cell growth/survival were assessed. Whereas the compound 
slightly affected GBM cell proliferation after 24 h of incubation (Fig. 4C), challenging cells for 72h 
with SA16 significantly decreased U87MG cell proliferation. These effects occurred in a 
concentration-dependent manner, with a maximal percentage of inhibition of 49.4 ± 2.0 % (Fig. 
4D), comparable to that obtained in the simultaneous presence of Alisertib and MP7 (58.5 ± 4.9%).  
As depicted in Supplementary Figure 8, SA16 significantly reduced the number of U87MG viable 
cells, and enhanced the number of dead cells (Supplementary Fig. 8), thus suggesting that the 
decrease of MTS measurements is associated with a reduction of cell viability.  
Comparable effects were obtained in ANGM-CSS cells, where the dual PDK1 inhibitor decreased 
GBM cell proliferation after 72 h of incubation, with a maximal percentage of inhibition of 54.9 ± 
4.5 % (Supplementary Fig. 9). Globally, these results demonstrate the great efficacy of the new 
compound in blocking proliferation/viability of different GBM cells. 
To investigate the preliminary toxicity profile of SA16, both human mesenchymal stem cells 
(MSCs) and human lymphocytes were used as normal non-cancer cells. Challenging MSCs with 
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SA16 (1-100 µM) for 72 h did not significantly affect cell proliferation (Fig. 4E). Similar results 
were obtained in human lymphocytes (Fig. 4F), thus suggesting that SA16 mechanism of action is 
directed preferentially toward tumour cells. 
Consistent with these data, Alisertib has been demonstrated to lack toxicity toward normal human 
astrocytes23. Similarly, PDK1 inhibitors have been extensively developed as anticancer drugs 
because of their low toxicity in normal cells44. For example, an allosteric inhibitor designed to 
impair PDK1 plasma membrane localisation has been shown to lack toxic effects in zebrafish 
embryos45. Thus, the dual inhibition of PDK1 and AurA kinases can represent a useful and non-
toxic therapeutic strategy in cancer. 
 
The dual-target compound induces GBM apoptosis and inhibit cell migration. 
The effect on GBM proliferation/viability was accompanied by cellular apoptosis. Indeed, 
challenging U87MG cells with SA16 for 72 h caused a significant induction of early and late 
apoptosis, as demonstrated by phosphatidylserine externalisation in the absence (early apoptosis), or 
in the presence of 7-amino-actinomysin binding to DNA (late apoptosis/death) (Fig. 5A and B). 
These data are consistent with the apoptotic effects elicited by the AurA blocker VX-68046. In the 
same paper, the authors found a correlation between cell sensitivity to AurA inhibitor and the 
phosphorylation status of Akt, suggesting a cooperation between AurA and Akt pathways46.  
Several data demonstrate a pivotal role for PDK1 in the regulation of cell migration7. Indeed, 
through the activation of multiple downstream effectors, this kinase represents a primary hub 
coordinating signals from extracellular cues to the cytoskeletal machinery, the terminal executor of 
cell movement7. On this basis, a scratch wound assay was performed following U87MG cell 
treatment with SA16 for 72 h. Representative images of control and treated U87MG cells are 
depicted in Figure 5C. Quantitative analysis of the gap area showed that SA16 significantly 
inhibited cell migration, both after 6 h and 24 h from the scratch (Fig. 5D). Globally, these results 
suggest that the new compound can efficaciously block U87MG cell migration, consistent with the 
data reported for MP712.  
We speculate that the effects elicited by SA16 on tumour migration can be mainly ascribed to the 
PDK1 inhibition, because the overexpression of this kinase has been shown to raise tumour  
invasiveness47, 48 and promote tumour growth in immunocompromised mice49. 
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The dual-target compound inhibits GSC formation and viability 
The effects of the new dual ligand were then assessed on the GSC subpopulation. SA16 induced a 
concentration-dependent inhibition of GSC proliferation, starting after four days of cell incubation 
(Fig. 6A and B). Following a seven-day treatment, the PDK1-AurA inhibitor yielded an IC50 value 
of 8.33 ± 0.78 nM and a maximal percentage of inhibition of 80.0 ± 2.0 % (Fig. 6B). Notably, the 
maximal effects of the co-treatment protocol Alisertib/MP7 (59.9 ± 2.9 %) were lower with respect 
to those obtained with the dual target compound SA16. 
Similar effects were noticed in GSC isolated from U343MG and ANGM-CSS cells (Supplementary 
Fig. 10A and B); indeed, SA16 displayed IC50 values of 49.7 ± 3.9 nM and 44.0 ± 3.6, and maximal 
percentages of inhibition of 81.4 ± 1.7 % and 77.0 ± 1.8 % in U343MG-GSCs and ANGM-CSS-
GSCs, respectively. These data demonstrate that the new compound can inhibit the stem-like 
population of GBM cells with great efficacy. Although a direct comparison between GSC and 
monolayer GBM cells is not possible, a preferential action of the compound toward neurospheres 
can be speculated. Indeed, CSCs have been shown to display extensive multiple kinase activation 
with respect to monolayer cells50, and to express higher AurA levels 51, implying that CSCs are 
intrinsically more sensitive to AurA or PDK1 inhibition than monolayer cultures. Consistent with 
this hypothesis, the AurA inhibition has been demonstrated to elicit higher antiproliferative effects 
to neurosphere cells than to standard monolayer GBM cells23.  
The SA16-mediated reduction of GSC proliferation was associated to apoptosis/death, as 
demonstrated by the significant induction of phosphatidylserine externalization in the presence of 7-
AAD binding to DNA (Fig. 6C and D). Globally, these results suggest that the dual target ligand is 
able to arrest GSC proliferation and induce their apoptosis. These effects can be attributed to both 
PDK1 or AurA block: indeed, a potent PDK1inhibitor has been demonstrated to reduce proliferation 
and to induce apoptosis of acute myeloid leukemia cells52, while Alisertib was found to exert 
growth inhibitory effects and trigger apoptosis/autophagy in a leukemia cell line53. 
Furthermore, the ability of SA16 to affect GSC self-renewal was examined. To this purpose, GSC 
cells were dissected and a soft-agar assay was performed. The effect of a sub-toxic dose of SA16 (1 
nM) was evaluated after 21 days of treatment (Fig. 6E-G). The results showed that the compound 
did not affect the total sphere number (Fig. 6E and G); conversely, the diameter of the newly formed 
spheres was significantly reduced in the presence of SA16 (Fig. 6E and F). These results suggest 
that SA16 has the ability to decrease the stem cell self-renewal ability of the GSCs. This effect can 
be ascribed to both PDK1 and AurA block. Indeed, Alisertib has been shown to potently inhibit the 
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self-renewal ability of GSCs23; similarly, PDK1 has been shown to deplete the CSC population in 
highly invasive breast cancer cells by decreasing tumorspheres formation34. 
 
The combined inhibition of PDK1 and AurA affects GSC morphology and stemness.  
The effects of SA16 on GSC morphology were evaluated by quantifying the area occupied by the 
cells in culture plates, as well as the outgrowth of cellular processes. When the cells were incubated 
with SA16 for seven days at different concentrations (1µM or 10µM), an almost complete reduction 
in the area occupied by the neurospheres was noticed (Fig. 7A and B), and the cells showed 
prominent outgrowth of processes (Fig. 7A and C).  
Real time PCR experiments (Fig. 7D) showed that the compound induced a significant transcription 
of the glial marker GFAP and of neuronal marker MAP2, thus suggesting that SA16 induced stem 
cell differentiation toward a neuronal and glial phenotype. These data were confirmed at the protein 
level by Western blotting (Fig. 8A and B), which showed a significant decrease of the stem cell 
marker Nestin, accompanied by a significant increase of GFAP protein levels.  
We then verified if adherent GBM cells could lose their stemness potential after drug treatment. To 
this purpose, stem cell markers were analysed in U87MG cells treated with SA16 for 72 h. As 
depicted in Figure 8C, the dual compound significantly reduced the mRNA transcription levels of 
the stemness markers CD133 and Nestin in the remaining adherent cells with respect to the initial 
cell population. 
Globally, these data demonstrate that PDK1-AurA inhibition is able to reduce GBM stemness 
potential. In agreement with our results, Alisertib was found to induce cellular differentiation in 
surviving GBM cells after its cytotoxic effect25, allowing the authors to hypothesize that this 
differentiating effect could be ascribed to an AurA inhibition-mediated decreased c-Myc and/or NFκ
B signalling. Indeed, c-Myc induces Nestin expression and the undifferentiated glioblastoma tumor 
stem cell phenotype54, while blockade of NFκB signalling cause senescence of differentiating 
glioblastoma cells55. 
 
Conclusions 
The Akt/PDK1 and AurA pathways play a pivotal role in GBM cellular survival/migration and in 
the self-renewal of the glioma stem cell component, and thus could represent an innovative strategy 
to overcome GBM resistance and recurrence. 
For the first time, the combined inhibition of the two kinases was investigated in GBM cells and in 
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the GSC subpopulation, using the reference compounds MP7 and Alisertib. Furthermore, SA16 was 
identified as a new ligand able to simultaneously inhibit both PDK1 and AurA kinases. This novel 
OXID-pyridonyl derivative was demonstrated to block GBM cell proliferation, reduce tumour 
invasiveness, and to trigger cellular apoptosis. Even more remarkable was the ability of the new 
AurA/PDK1 blocker to control GSCs by inducing their differentiation and apoptosis.  
To the best of our knowledge, this is the first study of a combinatorial treatment strategy that 
simultaneously inhibits both PDK1 and AurA pathways. Finally, the innovative PDK1/AurA dual-
target molecule we identified, SA16, provides a very promising multi-target approach to the 
treatment of GBM, with the added ability to deplete GSC population, and thus improve the 
prognosis of the disease. 
Additional experiments will be performed to explore in more detail the intracellular proteins 
involved in AuroraA/PDK1 crosstalk. AurA has been demonstrated to activate mTOR/Akt/PDK1 
pathway during cell transformation46, and a more malignant phenotype is observed in AurA cells 
containing a higher activation of mTOR/Akt/PDK1 signals, thus suggesting a strong link between 
these signalling pathways. 
 
Methods 
Chemistry. The synthetic Scheme followed for the preparation of SA16 is reported in 
Supplementary Section (Supplementary Scheme. 1). The experimental procedures to obtain the 
final product have been previously reported10. Briefly, the N-BOC-phenylalanine was condensed 
with the 5-amino-2-oxo-indole, which was successively deprotected and submitted to the reaction 
with the appropriate carboxylic acid in the presence of TBTU and DIPEA. Consequently, the 
Knoevenagel reaction with the commercially available 4-imidazolecarbaldehyde provided the final 
product SA16. 
 
Docking calculations. Molecular docking of the OXID-pyridonyl compound SA16 was carried out 
using the Glide 6.5 program58. Ligand structure was first generated through the Maestro sketcher 
and then prepared through the LigPrep module, as implemented in the Maestro 10.0.013 graphical 
user interface59. The seven receptor structures (PDB codes: 4CEG38; 4J8M40; 4UYN39; 4UZH39; 
3UOL42; 3H1037; 2C6E41) of AurA and the DFG-out conformation of PDK1 (PDB code: 3NAX)60 
were prepared through the Protein Preparation Wizard, also implemented in Maestro, and the 
OPLS-2005 force field. Water molecules and residual crystallographic buffer components were 
removed, missing side chains were built using the Prime module, hydrogen atoms were added, side 
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chains protonation states at pH 7.0 were assigned and, finally, minimization was performed until the 
RMSD of all the heavy atoms was within 0.3 Å of the positions determined by X-ray 
crystallography . In the specific case of the PDK1 DFG-out conformation, the salt bridge between 
Lys-111 and Glu-130 typical of the DFG-in conformation is disrupted. As Lys-111 is surrounded by 
several hydrophobic residues, the Protein Preparation Wizard assigned the neutral protonation state 
to this residue. The binding pocket was identified by placing a cube centered on the inhibitor 
molecules in complex with Aurora A or PDK1. The inner box size was chosen to be 15 Å in all 
directions and the size of the outer box was set by choosing a threshold length for the ligand size to 
be docked of 20 Å. Molecular Docking calculations were performed by means of Glide 6.5 in extra-
precision (XP) mode, using GlideScore for ligand ranking. A maximum of 10000 poses per ligand 
was set to pass to the grid refinement calculation and the best 1000 poses were kept for the energy 
minimization step. The maximum number of poses per ligand to be outputted was set to 10. Figures 
were generated using the UCSF-Chimera software package61. 
 
GBM cell culture and isolation of GSCs. U87MG, U343MG and ANGM-CSS were used as 
representative GBM cells and cultured as monolayer according to the respective cell line service. 
To isolate GSCs from each GBM cell line, approximately 2.0 x 106 cells were suspended in a 
specific serum-free Neural Stem Cell (NSC) medium32, lacking serum and containing basic 
fibroblast growth factor (20 ng/ml), epidermal growth factor (20 ng/ml) and B27 supplement (20 
µl/ml) 32. After 5–6 days of culture, the neurospheres were collected, suspended in NSC medium, 
dissociated into single cells and plated for the experiments.  
To characterize spheres isolated from GBM cells, real time PCR and western blotting analyses of 
stem cells markers were performed (see Supplementary Figure 3). Moreover, cells were assessed for 
their clonogenic potential, using a limiting dilution initiation analysis to quantify, in the GSC and 
U87MG adherent cells, the frequency of neurospheres-initiation cells (Supplementary Figure 4)62. 
Briefly, the U87MG adherent cells and the GSC were dissociated with trypsin/EDTA and seeded in 
NSC medium at a density of 1, 5, 10, 50 or 100 cells/well in a 96-multiwell plate. After two weeks 
of incubation, the formed neurospheres were counted. Wells containing neurospheres (almost 
exclusively one neurosphere per well) were scored, and the data generated computed using ELDA's 
online algorithm (http://bioinf.wehi.edu.au/software/elda/).  
For the colony formation analysis, GSCs were dissociated and seeded at density of 1 cell/well in 
NSC medium. Wells that contained a single cell was identified with microscopic observation, and 
the cells were maintained in NSC medium. After 14 days, colony formation was scored. The 
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percentage of cells that formed spheres was determined by the following equation: (Y(n)/X(n)) 
*100 where X(n) is the number of wells in which a single cell was present and Y(n) is the number 
of wells in which one neurosphere developed from a single cell. The mean percentage of wells 
containing one neurosphere was measured and the mean diameter was evaluated using Image J 
program. 
 
Isolation and culture of human MSC and T lymphocytes. Human MSCs (Lonza, Milan, Italy), 
were cultured in the specific growth medium, and maintained at 37 °C in 5% CO2. Mononuclear 
cell isolation was assessed according to the method of Boyum63, as previously reported64. MSCs (5 
x 103 cells/well) or lymphocytes were seeded in 96-multiwell plate and incubated for 72 h with the 
indicated concentrations of SA16. At the end of treatments, the compound toxicity was verified 
using the MTS assay, as described below. 
 
Cell proliferation assays of GBM cells and GSCs. The human GBM cells (i.e., U87MG, 
U343MG or ANGM-CSS) or the respective GSCs were seeded and incubated for the indicated 
times with the indicated concentrations of SA16 (1 nM-100 µM), MP712 or Alisertib23. When 
indicated, cells were treated with MP7 and Alisertib in combination. To verify GSC 
chemoresistance, U87MG or GSCs were incubated with 50 µM TMZ for 72 h. For the long-term 
treatment of cells, NSC or complete medium containing drugs was replaced every three days. Cell 
proliferation was determined using the MTS assay according to manufacturer's instruction65: the 
dehydrogenase activity in active mitochondria reduces 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxy 
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) to the soluble formazan product, whose 
absorbance at 490 nm was measured with an automated plate reader65. The mean background from 
each test condition was subtracted and the data were expressed as the percentage of untreated cells 
(control). IC50 values were derived from the sigmoid dose-response curve. The percentage of 
inhibition was calculated as 100 % minus the percentage of cell proliferation.  
 
Counting of viable and dead cells. GBM cells or GSCs were treated as described in the preceding 
paragraph. Following the treatment period, cell viability was determined using the Muse® Count & 
Viability Reagent (Merck KGaA, Darmstadt, Germany)66 according to manufacturer’s instruction.  
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Wound healing migration assay. The U87MG cell monolayer was incubated for 72 h with 10 µM 
SA16. The cells were then scratched as described10, and images of the closure of the scratch were 
captured at 0, 6, and 24 h.  
 
Apoptosis assessment  
U87MG or GSCs were incubated with SA16 for 72 h or 7 days, respectively. Following treatment, 
early and late apoptotic cells were distinguished by using the annexin V conjugated with fluorescein 
isothiocyanate (FITC) and amino-actinomycin D (7-AAD), using the Muse Apo Assays® (Merck-
Millipore) as reported before67. 
 
RNA extraction and real time PCR analysis  
U87MG or GSCs were incubated with SA16 for 72 h or 7 days, respectively. The mRNA levels of 
Nestin, MAP2 and GFAP were evaluated by quantitative real time PCR using Fluocycle® II 
SYBR® (Euroclone, Milan, Italy)68. The nucleotide sequences, annealing temperature and product 
size of the primers have been previously reported69. 
 
Quantification of the occupied area and the cellular processes of neurospheres. GSCs isolated 
from U87MG cells were plated in complete medium and treated for seven days with different 
concentration of SA16, MP7, Alisertib or a combination of MP7 and Alisertib. At the end of the 
treatment period, images were captured, and the area occupied by neurospheres that had formed, as 
well as the length of cellular processes were quantified as described32. Five different wells were 
analysed for each condition, with 15 images captured for each well32. Cellular processes were 
measured considering the average diameter of an individual neurosphere in the vertical and 
horizontal planes, and the neurite lengths were measured according to literature protocols32, 70. 
 
Colony forming assay. The self-renewal capability was assessed with the soft-agar colony forming 
assays66. Briefly, GSCs were dissociated, and 500 µl of 1x104 cells/ml were suspended in NSC 
medium containing 0.3% agar (low melting temperature agarose, Sigma-Aldrich, Milan, Italy). 500 
µl of the obtained suspension were treated with SA16 and were plated on a layer of 500 µl of the 
same medium containing 0.6% agar in a 24 well plate. The plates were fed weekly with 0.1 ml of 
NSC medium. Three weeks after plating, the photographs of the colonies were taken. The number 
of colonies derived by a single cell was evaluated and the images were analysed using Image J 
program. 
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Western blotting analysis. U87MG or GSCs were incubated with DMSO (control), or SA16 (10 
µM) for 72 h or seven days, respectively. At the end of the treatment periods, the cells were 
collected and lysed32. Cell extracts were resolved using SDS-PAGE, and the amount of proteins 
were detected using the primary antibodies described in Daniele, S.32. The Image J Software was 
used to perform the densitometric analysis of immunoreactive bands. 
 
Statistical analysis. Graph-Pad Prism (GraphPad Software Inc., San Diego, CA) was used for data 
analysis and graphic presentations. All data are presented as the mean ± SEM. One-way analysis of 
variance (ANOVA) with Bonferroni’s corrected t-test for post-hoc pair-wise comparisons was used 
to perform statistical analysis. 
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Supporting information 
Characterization of GSCs derived from U87MG cells, proliferation and viability experiments on 
U87MG, U343MG and ANGM-CSS cells, and results from SelectScreenTM Kinase Profiling 
Service for SA16, selection of receptor conformations for docking and crystallographic parameters 
of the analyzed AurA structures, synthetic scheme of SA16.  
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Figure Legends 
 
Fig. 1. (A) Crosstalk between the PDK1/AurA pathways. PDK1 phosphorilates Akt and 
Phospholipase C-Gamma 1 (PLCγ1), influencing apoptosis, cell proliferation, glucose metabolism 
and metastasis formation. Akt activity is also influenced by AurA. Aberrant AurA activity induces 
cell motility, cell stemnsess, proliferation and differentiation. PI3K, which activates the PDK1/Akt 
pathway, can influence AurA effect too. (B) Chemical formulas of MP7, Alisertib and SA16. 
 
Fig. 2. Effects of PDK1 and AurA inhibition on GBM and GSC proliferation. (A, B) U87MG cells 
(A) or GSCs (B) were incubated with the indicated concentrations of the PDK1 inhibitor MP7 or 
the AurA inhibitor Alisertib, alone or in combination, for 72 h or seven days, respectively. At the 
end of treatment, cell proliferation was evaluated as described in the Methods Section.  The data are 
expressed as a percentage with respect to that of untreated cells (control), which was set to 100% 
(mean values ± SEM, N = 3). * p<0.05, ** p<0.01, *** p<0.001 vs. control cells; # p<0.05, ## 
p<0.01, ### p<0.001 vs cells treated with MP7 alone; § p<0.05, §§ p<0.01, §§§ p<0.001 vs cells 
treated with Alisertib alone. 
 
Fig. 3. Effects of PDK1 and AurA inhibition on GSC morphology. (A-C) GSCs were incubated 
with complete medium containing DMSO (control), 2,5 µM MP7 and 1,5 µM Alisertib, alone or in 
combination, for seven days. (A) Representative cell micrographs after seven days of treatment are 
shown. The area of the culture plates occupied by the spheres (B) and the length of cellular 
processes (C) were scored after seven days of treatment (mean values ± SEM, N = 3). * p<0.05, *** 
p<0.001 vs. control, ## p<0.01 vs MP7 alone, § p<0.05 vs Alisertib alone. 
 
Fig. 4. (A, B) Binding mode of SA16 as found by the docking calculations within its A) PDK1 and 
B) AurA biding sites. Both SA16 (colored in orange) and the protein residues involved into binding 
are depicted as sticks. The structures of PDK1 and AurA are depicted as cartoons, colored in cyan 
and pink, respectively. (C, D) U87MG cells were treated in complete medium with the indicated 
concentrations of SA16 for 24 h (C) or 72 h (D), and cell proliferation was evaluated as described in 
the Methods Section. (E, F) Human MSCs (E) or lymphocytes (F) were treated with DMSO or the 
indicated SA16 concentrations. Following treatment, cell proliferation was evaluated as described 
in the Methods section. The data are expressed as a percentage with respect to that of untreated cells 
(control), which was set to 100% (mean values ± SEM, N = 3). * p<0.05, ** p<0.01, *** p<0.001 
vs. control. 
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Fig. 5. SA16 induces GBM cell apoptosis and inhibits cell migration. (A, B) U87MG cells were 
incubated with DMSO (control), or 10 µM SA16 for 72 h. At the end of the treatment period, the 
cells were collected, and the level of phosphatidylserine externalisation was evaluated using the 
Annexin V-staining protocol. (B) The data are expressed as the percentage of apoptotic cells  versus 
the total number of cells (mean values ± SEM, N = 3). The data for the early-stage apoptotic cells 
are shown in white, while the data for the late-stage apoptotic/necrotic cells are shown in grey. * 
p<0.05, *** p<0.001 vs. control. (C, D) U87MG cells were treated for 72 h with DMSO (control), 
or 10 µM SA16. Following treatment, the cell monolayer was scratched (time zero), and cells were 
grown in fresh medium. Representative micrographs were taken after 6 h and 24 h from the scratch 
(C). The gap area (D) was measured after 6 h and 24 h from the scratch (mean values ± SEM, N = 
3). *** p<0.001 vs control; ### p<0.001 vs respective gap area at 6 h from the scratch.  
 
Fig. 6. SA16 induces GSC apoptosis and blocks GSC formation (A, B) U87MG-derived GSCs were 
incubated with different concentrations of SA16 for four days (A) or seven days (B). At the end of 
treatment, cell proliferation was evaluated as described in the Methods Section. (C, D) GSCs were 
treated as in B, and the apoptosis degree was evaluated using the Annexin V protocol. (C) The data 
were expressed as the percentage of apoptotic cells (early-apoptotic is represented in white, late-
apoptotic/necrotic in grey) relative to the total number of cells (mean values ± SEM, N = 3). (E-G) 
For the soft-agar assay the GSC cells were treated with DMSO or SA16 (1 nM) in NSC medium for 
21 days. (E) Representative pictures of the cells after 21 days of incubation were shown. The mean 
diameter (F) and the number of the newly formed spheres (G) were scored. * p<0.05, ** p<0.01, 
*** p<0.001 vs. control. 
 
Fig. 7. SA16 induces GSC differentiation. GSCs were incubated for seven days with complete 
medium containing DMSO (control), or the indicated concentrations of SA16. (A) Representative 
cell micrographs after seven days of treatment are shown. The area occupied by the cells in culture 
plates (B) and the outgrowth of cellular processes (C) were scored after seven days of treatment 
(mean values ± SEM, N = 3). (D) Total RNA was extracted and the relative mRNA quantification of 
the stem cell marker Nestin, the neuronal marker MAP2 and the astrocyte marker GFAP was 
performed by RT-PCR. The data are expressed as the fold change vs. the levels of the control (mean 
values ± SEM, N = 3). * p<0.05, **p<0.01, *** p<0.001 vs. control. 
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Fig. 8. SA16 reduces GBM stemness potential (A, B) GSCs were treated with DMSO (control) or 
10 µM SA16 for seven days; the protein levels of the stemness marker Nestin and of the glial 
marker GFAP were assessed by Western blotting, using GAPDH as the loading control. (C) 
U87MG were incubated with SA16 for 72 h. (C) Total RNA was extracted and the relative mRNA 
quantification of the stem cell markers Nestin and CD133 was performed by RT-PCR. The data are 
expressed as the fold change vs. the levels of the control (mean values ± SEM, N = 3). * p<0.05, 
**p<0.01, *** p<0.001 vs. control. 
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